Abstract：
BACKGROUND: Monocyte-macrophage lineage cells are committed towards osteoclast differentiation in vitro by the downregulation of microphthalmia-induced transcription factor (MITF) by miRNA-155. Therefore, we aimed to evaluate miRNA-155 expression and explore the regulation of MITF by miRNA-155 during osteoclastogenesis in periodontitis.
METHODS: Ninety-eight subjects were recruited and categorized into the following: group I (cases)-systemically healthy with localized stage III/IV periodontitis (N = 49) and group II (controls)-systemically and periodontally healthy (N = 49). Gingival tissue samples were procured and qRT-PCR analysis was carried out for relative gene expression.
RESULTS: The mean ΔCT of miRNA-155 expression was -1.04 ± 2.26 and -0.01 ± 1.4 respectively for groups I and II. There was a statistically significant difference in the miRNA-155 expression (P ≤ 0.01) between the groups. The mean ΔCT of MITF expression for groups I and II was 4.15± 2.16 and 3.51± 1.57 respectively with no significant difference (P > 0.01) between the groups. In the periodontitis group, miRNA-155 expression increased by fivefolds (P ≤ 0.01) whereas MITF expression showed no significant difference in the fold change between the groups (P > 0.01). The site-specific clinical parameters showed a statistically significant strong negative and positive correlation with the ΔCT and fold change values of miRNA-155 respectively in the total 98 samples (P < 0.01). miRNA-155 was able to discriminate between periodontal health and disease with a diagnostic accuracy of 96.9% (95%CI: 91.38-98.95) and the AUC was 0.98 (95%CI: 0.97-1.0, SE = 0.008, P < 0.001) in ROC analysis with a sensitivity of 93.8% (95%CI: 83.48-97.9) and specificity of 100% (95%CI: 92.73-100).
CONCLUSIONS: miRNA-155 was dysregulated and upregulated by fivefolds in periodontal disease. It can be used as a potential biomarker to discriminate between periodontal health and disease. No difference in the MITF gene expression was demonstrated between periodontal health and disease. The result suggested that miRNA-155 does not affect the expression of MITF gene in the process of osteoclastogenesis in localized stage III/IV periodontitis within this study design and limitations.
METHODS: Ninety-eight subjects were recruited and categorized into the following: group I (cases)-systemically healthy with localized stage III/IV periodontitis (N = 49) and group II (controls)-systemically and periodontally healthy (N = 49). Gingival tissue samples were procured and qRT-PCR analysis was carried out for relative gene expression.
RESULTS: The mean ΔCT of miRNA-155 expression was -1.04 ± 2.26 and -0.01 ± 1.4 respectively for groups I and II. There was a statistically significant difference in the miRNA-155 expression (P ≤ 0.01) between the groups. The mean ΔCT of MITF expression for groups I and II was 4.15± 2.16 and 3.51± 1.57 respectively with no significant difference (P > 0.01) between the groups. In the periodontitis group, miRNA-155 expression increased by fivefolds (P ≤ 0.01) whereas MITF expression showed no significant difference in the fold change between the groups (P > 0.01). The site-specific clinical parameters showed a statistically significant strong negative and positive correlation with the ΔCT and fold change values of miRNA-155 respectively in the total 98 samples (P < 0.01). miRNA-155 was able to discriminate between periodontal health and disease with a diagnostic accuracy of 96.9% (95%CI: 91.38-98.95) and the AUC was 0.98 (95%CI: 0.97-1.0, SE = 0.008, P < 0.001) in ROC analysis with a sensitivity of 93.8% (95%CI: 83.48-97.9) and specificity of 100% (95%CI: 92.73-100).
CONCLUSIONS: miRNA-155 was dysregulated and upregulated by fivefolds in periodontal disease. It can be used as a potential biomarker to discriminate between periodontal health and disease. No difference in the MITF gene expression was demonstrated between periodontal health and disease. The result suggested that miRNA-155 does not affect the expression of MITF gene in the process of osteoclastogenesis in localized stage III/IV periodontitis within this study design and limitations.
摘要：
背景：通过miRNA-155下调小眼症诱导的转录因子（MITF），单核细胞-巨噬细胞谱系细胞在体外致力于破骨细胞分化。因此,我们的目的是评估miRNA-155的表达，并探讨miRNA-155在牙周炎破骨细胞形成过程中对MITF的调控。
方法：招募了98名受试者，并分为以下几类：I组（病例）-全身健康，局部III/IV期牙周炎（N=49）和II组（对照）-全身和牙周健康（N=49）。获取牙龈组织样品,并对相对基因表达进行qRT-PCR分析。
结果:对于I组和II组,miRNA-155表达的平均ΔCT分别为-1.04±2.26和-0.01±1.4。各组miRNA-155表达差异有统计学意义(P≤0.01)。I组和II组MITF表达的平均ΔCT分别为4.15±2.16和3.51±1.57，组间差异无统计学意义（P>0.01）。在牙周炎组中，miRNA-155表达增加五倍（P≤0.01），而MITF表达在各组之间的倍数变化没有显着差异（P>0.01）。在总共98个样品中,位点特异性临床参数分别与miRNA-155的ΔCT和倍数变化值显示出统计学上显著的强负相关和正相关(P<0.01)。miRNA-155能够区分牙周健康和疾病，诊断准确率为96.9%(95CI:91.38-98.95)，ROC分析AUC为0.98(95CI:0.97-1.0，SE=0.008，P<0.001)，灵敏度为93.8%(95CI:83.48-97.9)，特异性为100%(95CI:92.73-100)。
结论：miRNA-155在牙周病中失调并上调五倍。它可以用作区分牙周健康和疾病的潜在生物标志物。在牙周健康和疾病之间，MITF基因表达没有差异。结果提示miRNA-155在本研究设计和局限性内不影响局部III/IV期牙周炎破骨细胞形成过程中MITF基因的表达。
方法：招募了98名受试者，并分为以下几类：I组（病例）-全身健康，局部III/IV期牙周炎（N=49）和II组（对照）-全身和牙周健康（N=49）。获取牙龈组织样品,并对相对基因表达进行qRT-PCR分析。
结果:对于I组和II组,miRNA-155表达的平均ΔCT分别为-1.04±2.26和-0.01±1.4。各组miRNA-155表达差异有统计学意义(P≤0.01)。I组和II组MITF表达的平均ΔCT分别为4.15±2.16和3.51±1.57，组间差异无统计学意义（P>0.01）。在牙周炎组中，miRNA-155表达增加五倍（P≤0.01），而MITF表达在各组之间的倍数变化没有显着差异（P>0.01）。在总共98个样品中,位点特异性临床参数分别与miRNA-155的ΔCT和倍数变化值显示出统计学上显著的强负相关和正相关(P<0.01)。miRNA-155能够区分牙周健康和疾病，诊断准确率为96.9%(95CI:91.38-98.95)，ROC分析AUC为0.98(95CI:0.97-1.0，SE=0.008，P<0.001)，灵敏度为93.8%(95CI:83.48-97.9)，特异性为100%(95CI:92.73-100)。
结论：miRNA-155在牙周病中失调并上调五倍。它可以用作区分牙周健康和疾病的潜在生物标志物。在牙周健康和疾病之间，MITF基因表达没有差异。结果提示miRNA-155在本研究设计和局限性内不影响局部III/IV期牙周炎破骨细胞形成过程中MITF基因的表达。
